Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
64
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,579.90 | 50.10 | 0.59% |
CAC 40 | 7,886.69 | 33.22 | 0.42% |
DAX 40 | 23,767.43 | 71.84 | 0.30% |
Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
FTSE 100 | 8,684.56 | 50.81 | 0.59% |
HKSE | 23,345.05 | 108.11 | -0.46% |
NASDAQ | 19,211.10 | 98.78 | 0.52% |
Nikkei 225 | 37,753.72 | 1.79 | -0.00% |
NZX 50 Index | 12,786.79 | 94.03 | -0.73% |
S&P 500 | 5,958.38 | 41.45 | 0.70% |
S&P/ASX 200 | 8,343.70 | 46.20 | 0.56% |
SSE Composite Index | 3,367.46 | 13.36 | -0.40% |